In the CERE-LYSE study, the combination of Cerebrolysin (30 mL/day, for 10 days) with r-tPA in humans was safe although it did not significantly improve functional outcome in the modified Rankin Scale (mRS) at 3 months, but in the National Institutes of Health Stroke Scale (NIHSS) responder analysis (secondary outcome measure) significantly more patients had an improvement of 6 or more points after two-, five-, 10, and 30 days in the Cerebrolysin group (31). The gene discussed is PLAT; the disease is stroke disorder.